Li David H sold $762K of NGVT

Li David H (President & CEO) sold 10,000 shares of Ingevity Corp (NGVT) at an average of $76.18 ($75.73–$76.62, $0.76M total) across 2 trades over 2026-08-12 to 2026-08-13 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Li David H
Published Aug 14, 2026, 9:06 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 14, 2026, 11:52 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$NGVT
Neutral
high confidence
Mentioned
$NGVT
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$NGVTNeutralLow
01

Why it matters

The only new information is the disclosed sale size, dates, and price range under a pre-arranged 10b5-1 plan; there is no mention of earnings, guidance, litigation, or business developments.

02

Market read

Traders may briefly reassess sentiment around insider behavior, but the 10b5-1 structure and lack of fundamental updates suggest limited trading edge.

03

What to watch

The article does not state whether sales were part of a larger scheduled program or whether there were concurrent purchases, so the net insider posture is incomplete.

Relevance 4/10Novelty 3/10Timing: filed on 2026-08-14 after Aug 12-13 sales

Background

The article is an SEC Form 4 insider transaction disclosure for Ingevity (NGVT) by its President and CEO, Li David H.

Company-level read

Ticker impact

$NGVTNeutralHigh confidence
Context

Ingevity CEO Li David H sold about 10,000 shares in Aug 12-13 under a 10b5-1 plan, worth about $761,750.

Expected impact

Likely limited near-term impact; any reaction should be muted unless paired with other new disclosures.

Evidence & confidence

The filing is a Form 4 insider transaction with explicit 10b5-1 pre-arrangement and no accompanying operational or financial guidance changes in the text.

Market effects

No sector-level signal is provided; this is company-specific insider activity.

None indicated.

None indicated.

Counterpoint

Insider sales can be purely liquidity-driven even when they look bearish; the 10b5-1 flag reduces interpretive weight.

Key entities

  • Ingevity Corp

    Subject of the Form 4 insider sale disclosure.

  • Li David H

    President and CEO who executed the open-market sale under a 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$NGVTMed

Ingevity (NGVT) Lifted EPS Guidance, Is The Stock Still Cheap?

Ingevity (NGVT) raised its full-year EPS guidance despite lower Q3 sales. The stock has fallen 15.34% in the past week but remains up 25.15% over one year. Analysts estimate fair value at $89, suggesting a 30% undervaluation, though its P/E ratio is higher than industry averages. The company plans $300M in share buybacks by 2027.

$NGVTHighAI 8/10

Ingevity Q3 Earnings Call Highlights

Ingevity (NGVT) reports Q3 earnings, highlighting growth in hybrid vehicle and filtration markets. CEO Dave Li notes benefits from the hybrid transition and new water treatment contracts. Pavement Technologies sales fell 24% due to divestiture and higher asphalt costs. Advanced Polymer Technologies sales rose 18%. The company narrowed its 2026 adjusted EBITDA outlook to $385M-$395M and expects $1.1B in sales. Ingevity repurchased $39M in shares during Q3.

$NGVTMed

Ingevity (NGVT) Q3 2026 Earnings Call Transcript

Ingevity (NGVT) reported Q3 2026 sales of $305M, down 8% YoY due to divestitures, but up 2% excluding them. Adjusted EBITDA was $108M, down 2%, with margins expanding to 35.4%. EPS rose 24% to $1.63. The company highlighted growth in filtration and water treatment, secured new contracts, and repurchased $39M in shares. Full-year adjusted EBITDA is expected to be $385M-$395M, with sales around $1.1B and EPS of $5.25-$5.45.

$NGVTMed

Ingevity reports third quarter 2026 financial results

Ingevity Corp (NGVT) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Ingevity Corporation 4920 O'Hear Avenue Suite 400 North Charleston, SC 29405 USA www.ingevity.com Ingevity reports third quarter 2026 financial results Third Quarter 2026 Results and Recent Highlights: • Net sales of $305.1 million decreased 8% from prior year; exclu

$NGVTHigh

Ingevity reports third quarter 2026 financial results

Ingevity reported Q3 2026 net sales of $305.1M, down 8% YoY. Net income rose to $51.1M per diluted share. Adjusted EBITDA fell $108M but margin expanded to 35.4%. The company narrowed its full-year adjusted EBITDA outlook to $385M-$395M. CEO Dave Li cited strong Performance Materials but noted challenges in Pavement Technologies. Ingevity (NYSE: NGVT) plans to host an earnings call on November 5, 2026.